Skip to main content

Table 2 Total PRISM score according to treatment group, evaluation moment and phase of the menstrual cycle

From: Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study

Period

Treatment Groups

Difference between groups p-value*

 

A (1 g)

B (2 g)

C (Placebo)

 
 

Median (P25 - P75)

Median (P25 - P75)

Median (P25 - P75)

 

Pretreatment

    

Follicular

29 (19 - 63)

27 (17 - 37)

28.5 (19 - 33)

A X B: 0.2629

Luteal

99 (87 - 162)

98 (82 - 123)

96.5 (89 - 117)

A X C: 0.3130

Difference

77 (61 - 94)

73 (51 - 84)

74 (49 - 88)

B X C: 0.9878

p-valueΔ

< 0.001

< 0.001

< 0.001

 

3 months

    

Follicular

17 (11 - 38)

21 (15 - 25)

25.5 (18 - 31)

A X B: 0.0017

Luteal

58 (42 - 79)

48 (41 - 61)

88.5 (78 - 109)

A X C: 0.0001

Difference

41 (26 - 50)

27 (20 - 34)

63.5 (48 - 79)

B X C: <0.001

p-valueΔ

< 0.001

< 0.001

< 0.001

 

6 months

    

Follicular

08 (05 - 28)

09 (07 - 12)

25 (16 - 31)

A X B: 0.0029

Luteal

35 (31 - 56)

28 (24 - 35)

89 (74 - 105)

A X C: <0.001

Difference

27 (18 - 33)

18 (12 - 23)

62 (41 - 75)

B X C: <0.001

p-valueΔ

< 0.001

< 0.001

< 0.001

 
  1. Δ Comparison of the PRISM scores between the follicular and luteal phases (Wilcoxon's signed-rank test) within each treatment group.
  2. * Comparison of the difference in PRISM score between the follicular and luteal phases among the three groups (Mann-Whitney test).
  3. P25: 1st quartile
  4. P75: 3rd quartile